表 1.
正在进行的有关肺癌的ADCs联合治疗研究
Currently ongoing trials for the combination regimen of ADCs with other drugs in lung cancer
| Antigen target | ADC drug name | NCT number | Study agents | Study phase (n) | Study population | Primary endpiont |
| ADC: antibody-drug conjugates; NCT: national clinical trial; N: number; HER2: human epidermal growth factor receptor 2; NSCLC: non-small cell lung cancer; CEACAM5: carcinoembryonic antigen-related cell adhesion molecule 5; DLT: dose-limiting toxicity; MTD: maximum tolerated dose; ORR: overall response rate; PD-1: programmed death 1; PD-L1: programmed death-ligand 1; TROP2: trophoblast cell-surface antigen 2; EGFR: epidermal growth factor receptor; TKI: tyrosine kinase inhibitor; HER3: human epidermal growth factor receptor 3; ALK: anaplastic lymphoma kinase. | ||||||
| HER2 | T-DXd | NCT04042701 | T-DXd+Pembrolizumab | Ⅰ (115) | HER2-expressing locally advanced/metastatic breast cancer, and HER2-expressing or mutant locally advanced/metastatic NSCLC | DLT; MTD; ORR |
| CEACAM5 | SAR408701 | NCT04524689 | SAR408701+Pembrolizumab+ Cisplatin/Carboplatin±Pemetrexed | Ⅱ(96) | CEACAM5+, advanced or metastatic, non squamous NSCLC with no EGFR sensitizing mutation or BRAF mutation or ALK/ROS alterations | DLT |
| AXL | BA3011 | NCT04681131 | BA3011 or BA3011+PD-1 inhibitor | Ⅱ(240) | Metastatic NSCLC with prior disease progression on a PD-1/PD-L1 inhibitor | ORR; Safety |
| TROP2 | DS-1062 | NCT04612751 | DS-1062+Durvalumab±Carboplatin | ⅠB (68) | Advanced or metastatic NSCLC | DLT; MTD |
| HER2 | T-DXd | NCT04686305 | T-DXd+Durvalumab+Cisplatin/Carboplatin±Pemetrexed | ⅠB (136) | HER2 positive advanced and metastatic NSCLC | Safety |
| CEACAM5 | SAR408701 | NCT04394624 | SAR408701+Ramucirumab | Ⅱ(36) | Pre-treated non squamous NSCLC with CEACAM5 expression | DLT; ORR |
| HER2 | T-DM1 | NCT03784599 | T-DM1+Osimertinib | Ⅱ(58) | NSCLC with resistance to a first, second or third generation EGFR-TKI-treatment, and HER2-overexpression | Safety; ORR |
| HER3 | U3-1402 | NCT04676477 | U3-1402+Osimertinib | Ⅰ (252) | Locally advanced or metastatic EGFR-mutant NSCLC with treatment with osimertinib at least six weeks | DLT; ORR; Safety |
| TROP2 | SKB264 | NCT05351788 | SKB264+KL-A167± Cisplatin/Carboplatin | Ⅱ(110) | Locally advanced/metastatic NSCLC | Safety; ORR |